Nothing Special   »   [go: up one dir, main page]

NO20065717L - Substituerte N-arylbenzamider og beslektede forbindelser for behandling av amyloidsykdommer og synukleinopatier. - Google Patents

Substituerte N-arylbenzamider og beslektede forbindelser for behandling av amyloidsykdommer og synukleinopatier.

Info

Publication number
NO20065717L
NO20065717L NO20065717A NO20065717A NO20065717L NO 20065717 L NO20065717 L NO 20065717L NO 20065717 A NO20065717 A NO 20065717A NO 20065717 A NO20065717 A NO 20065717A NO 20065717 L NO20065717 L NO 20065717L
Authority
NO
Norway
Prior art keywords
synucleinopathies
treatment
substituted
arylbenzamides
amyloid diseases
Prior art date
Application number
NO20065717A
Other languages
English (en)
Inventor
Alan D Snow
Beth P Nguyen
Thomas P Lake
Gerardo M Castillo
Manfred Weigele
Original Assignee
Proteotec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteotec Inc filed Critical Proteotec Inc
Publication of NO20065717L publication Critical patent/NO20065717L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

Det beskrives substituerte diarylforbindelser med formlene (I, II og III) der variablene er som definert i kravene, samt deres farmasøytisk akseptable derivater. Videre beskrives forbindelsenes syntese, farmasøytiske preparater inneholdende forbindelsene samt deres anvendelse ved behandling av amyloidsykdommer inkludert Aß-amyloidose slik det observeres ved Alzheimers sykdom, IAPP-amyloidose, slik det observeres ved type 2-diabetes og synukleinopatier slik det observeres ved Parkinsons sykdom. Videre beskrives fremstilling av medikamenter for slike behandlinger.
NO20065717A 2004-05-12 2006-12-12 Substituerte N-arylbenzamider og beslektede forbindelser for behandling av amyloidsykdommer og synukleinopatier. NO20065717L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57066904P 2004-05-12 2004-05-12
US62952504P 2004-11-18 2004-11-18
PCT/US2005/016677 WO2005113489A1 (en) 2004-05-12 2005-05-12 Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies

Publications (1)

Publication Number Publication Date
NO20065717L true NO20065717L (no) 2007-02-08

Family

ID=34969702

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065717A NO20065717L (no) 2004-05-12 2006-12-12 Substituerte N-arylbenzamider og beslektede forbindelser for behandling av amyloidsykdommer og synukleinopatier.

Country Status (18)

Country Link
US (2) US7745490B2 (no)
EP (1) EP1751097B1 (no)
JP (1) JP5203701B2 (no)
KR (1) KR101168451B1 (no)
AT (1) ATE453617T1 (no)
AU (1) AU2005245412B2 (no)
BR (1) BRPI0510803A (no)
CA (1) CA2566090C (no)
DE (1) DE602005018634D1 (no)
DK (1) DK1751097T3 (no)
ES (1) ES2337162T3 (no)
IL (1) IL179160A (no)
MX (1) MXPA06012603A (no)
NO (1) NO20065717L (no)
NZ (1) NZ551589A (no)
RU (1) RU2381213C2 (no)
SG (1) SG137850A1 (no)
WO (1) WO2005113489A1 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090124690A1 (en) * 2000-04-03 2009-05-14 Alberte Randall S Generation of Combinatorial Synthetic Libraries and Screening for Novel Proadhesins and Nonadhesins
US20070208087A1 (en) * 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
BRPI0709699A2 (pt) * 2006-03-29 2011-07-26 Foldrx Pharmaceuticals Inc inibiÇço da toxidez da alfa-sinucleina
WO2009111611A2 (en) * 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
EP2098226A1 (de) * 2008-03-06 2009-09-09 Forschungsverbund Berlin e.V. AKAP-PKA-Interaktionshemmer zur Anwendung in der Behandlung von Herzkrankheiten
EP2554163A4 (en) * 2010-03-26 2013-07-17 Univ Hokkaido Nat Univ Corp THERAPEUTIC ACTIVE FOR NEURODEGENERATIVE DISEASES
US20120251448A1 (en) * 2011-03-03 2012-10-04 Hefti Franz F Compounds for Use in the Detection of Neurodegenerative Diseases
CN111315735B (zh) 2017-09-04 2024-03-08 C4医药公司 二氢苯并咪唑酮
KR102011033B1 (ko) * 2017-09-25 2019-08-14 (주)아모레퍼시픽 성분 함량이 변화된 녹차 추출물을 포함하는 인지기능 개선용 조성물
US10799551B2 (en) 2017-09-25 2020-10-13 Amorepacific Corporation Composition for enhancing cognitive function comprising green tea extract which has modified amounts of ingredients
US20220041591A1 (en) * 2018-10-19 2022-02-10 Auckland Uniservices Limited Compounds for treating diabetes and/or related conditions
WO2020181232A1 (en) 2019-03-06 2020-09-10 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
WO2023224893A1 (en) * 2022-05-20 2023-11-23 Merck Sharp & Dohme Llc Inhibitors of msba as antibiotics, pharmaceutical compositions, and uses thereof
WO2024067560A1 (zh) * 2022-09-26 2024-04-04 中国药科大学 磺酰胺类化合物及其医药用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5916871A (ja) * 1982-07-20 1984-01-28 Shionogi & Co Ltd スルホンアミド系ベンズアミド類
JPS63132237A (ja) * 1986-11-21 1988-06-04 Konica Corp 迅速処理を行なつても優れた発色性を有するハロゲン化銀写真感光材料
MX9203460A (es) * 1988-09-12 1992-09-01 Upjohn Co Nuevos analogos cc-1065 que tienen dos subunidades cpi.
GB8914660D0 (en) * 1989-06-26 1989-08-16 Fujisawa Pharmaceutical Co Aniline derivatives,processes for production thereof and pharmaceutical compositions comprising the same
JPH04285955A (ja) * 1991-03-14 1992-10-12 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
HUP0102128A3 (en) * 1998-05-22 2002-05-28 Avanir Pharmaceuticals San Die Mediciaments containing benzimidazole derivatives as modulators of ige
UA73284C2 (en) * 1998-10-22 2005-07-15 Substituted phenyl derivatives, a method for the preparation thereof (variants), a pharmaceutical composition based thereon (variants)
JP4623453B2 (ja) * 1999-10-14 2011-02-02 旭化成イーマテリアルズ株式会社 アミドフェノール化合物
PT2527315E (pt) * 2002-05-31 2014-06-24 Proteotech Inc Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
EP1556035A4 (en) * 2002-09-20 2006-09-13 Genelabs Tech Inc NEW AROMATIC COMPOUNDS WITH ANTIMYCOTIC OR ANTIBACTERIAL EFFECT

Also Published As

Publication number Publication date
NZ551589A (en) 2009-10-30
ES2337162T3 (es) 2010-04-21
JP5203701B2 (ja) 2013-06-05
IL179160A0 (en) 2007-03-08
WO2005113489A1 (en) 2005-12-01
US20090060838A1 (en) 2009-03-05
RU2006143761A (ru) 2008-06-20
DE602005018634D1 (de) 2010-02-11
EP1751097B1 (en) 2009-12-30
MXPA06012603A (es) 2007-04-12
BRPI0510803A (pt) 2007-11-06
US20060199838A1 (en) 2006-09-07
DK1751097T3 (da) 2010-05-10
EP1751097A1 (en) 2007-02-14
CA2566090C (en) 2013-07-23
KR101168451B1 (ko) 2012-07-25
KR20070015612A (ko) 2007-02-05
AU2005245412B2 (en) 2011-08-04
SG137850A1 (en) 2007-12-28
CA2566090A1 (en) 2005-12-01
AU2005245412A1 (en) 2005-12-01
ATE453617T1 (de) 2010-01-15
JP2007537287A (ja) 2007-12-20
IL179160A (en) 2011-04-28
US7745490B2 (en) 2010-06-29
RU2381213C2 (ru) 2010-02-10

Similar Documents

Publication Publication Date Title
NO20065717L (no) Substituerte N-arylbenzamider og beslektede forbindelser for behandling av amyloidsykdommer og synukleinopatier.
DK1689721T3 (da) Aminopyrazolderivater som GSK-3-ihibitorer
SE0104341D0 (sv) New use
DK2527315T3 (da) Forbindelser, præparater og fremgangsmåder til behandling af amyloide sygdomme og synukleinopatier, såsom Alzheimers sygdom, type 2-diabetes og Parkinsons sygdom
NO20052223L (no) Tiazolforbindelser for behandling av neurodegenerative forstyrrelser
BR0210391A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
DE60325074D1 (de) Kristall für ein orales, festes arzneimittel, und ein orales, festes arnzeimittel zur behandlung von dysurie, das diesen enthält
UA92181C2 (ru) Производные пиримидина и их применение в терапии и в производстве лекарственного средства для предотвращения и/или лечения болезни альцгеймера
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
EA200500006A1 (ru) Лекарственное средство для лечения нейродегенеративных заболеваний
NO20085323L (no) Smeltede, tricykliske sulfonamidinhibitorer av gammasekretase
TW200736255A (en) 5-(Substituted)-pyrazolopiperidines
NO20082673L (no) Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens
NO20075365L (no) 3,4-substituerte pyrrolidinderivater for behandling av hypertensjon
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
ATE253918T1 (de) Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel
NO20064010L (no) Indazolderivater og farmasoytiske preparater inneholdelse slike
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
NO20061702L (no) Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og en ostrogen agonist/antagonist
ATE409480T1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BR0210392A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
ATE403428T1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application